Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 107,738 shares, an increase of 93.0% from the January 15th total of 55,812 shares. Based on an average trading volume of 2,264,204 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 2,264,204 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BAYRY. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Three equities research analysts have rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock opened at $13.50 on Friday. The business has a fifty day moving average of $11.80 and a 200 day moving average of $9.39. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $13.98. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The firm has a market capitalization of $53.06 billion, a price-to-earnings ratio of -149.98, a price-to-earnings-growth ratio of 4.89 and a beta of 0.68.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.